-
Cetero Research Launches Seminar Series On Accelerated Proof-Of-Concept In Drug Development
9/2/2010
Cetero Research, the leading early-stage contract research organization (CRO), is launching a series of scientific seminars, "An Accelerated Path to Proof-of-Concept in Drug Development," designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase I and IIa clinical trial designs.
-
Addex Drug-Candidate Effective In Alzheimer’s Disease Model
9/2/2010
Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011.
-
ReproCELL Announces New Line Of Services In Neuronal Research Using Human iPS Cells
9/2/2010
ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) is pleased to announce a new line of products to be launched in the autumn of 2010, offering neuronal cells derived from human iPS (induced pluripotent stem) cells
-
Adimab Selected As Technology Pioneer 2011 By World Economic Forum
9/1/2010
The World Economic Forum recently announced that Adimab has been selected as a 2011 Technology Pioneer. To be selected as a World Economic Forum Technology Pioneer, a company must be involved in the development of a major technology or innovation and have the potential for long-term impact on business and society
-
BIOCIUS Life Sciences Expands Contract Research Service With New ADME Assay Analysis
9/1/2010
BIOCIUS Life Sciences Inc., developers of the RapidFire high-throughput mass spectrometry system, today announced a new contract research service that expands the in vitro ADME (Absorption, Distribution, Metabolism and Excretion) assays that can be analyzed quickly and efficiently using RapidFire technology
-
Golden Helix Partners With CloudScientific To Provide Genetic Analysis Software In China
8/31/2010
Golden Helix, Inc., a global leader in genetic analysis solutions, today announced that it has entered into an agreement with CloudScientific, a Chinese life sciences software company, to act as a distributor of the company's analytic services and proprietary software, the SNP & Variation Suite
-
TPP Global Development Ltd Enters Into An Agreement With The University Of Edinburgh For Future Drug Development
8/31/2010
TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University. TPP and the University of Edinburgh will focus on commercialisation opportunities in the areas of nervous system disorders, immunology/inflammation and oncology
-
KYTHERA And Bayer Dermatology Unit Intendis Enter Licensing And Development Agreement For Adipolytic Agent ATX-101
8/30/2010
KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada.
-
Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed At Resetting The Body Clock
8/30/2010
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.
-
New Toolkit For Docking Released By OpenEye Scientific Software
8/24/2010
OpenEye Scientific Software, Inc., the developer of innovative molecular modeling and cheminformatics solutions for drug discovery, announced the first release of the Docking TK as part of the OpenEye Toolkit v1.7.4 release
